Clinical Trial Update: Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing icotinib to first-line chemotherapy with maintenance in EGFR-positive lung adenocarcinoma; completed study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: NSCLC | Phase 3 | Status: COMPLETED